Table 1.
FDA approved drugs for treatment in HIV-1 infected patients. Drugs are classified on the basis of their viral or cellular targets. Brand name of the drugs are in italics.
| Reverse Transcriptase | Protease | Integrase | Fusion | CCR5 | |
|---|---|---|---|---|---|
| NRTIs | NNRTIs | ||||
| Abacavir (ABC) Ziagen | Delavirdine (DLV) Rescriptor | Amprenavir (APV) Agenerase | Raltegravir (RAL) Isentress | Enfuvirtide (T20) Fuzeon | Maraviroc (MVC) Selzentry |
| Didanosine (ddI) Videx | Efavirenz (EFV) Sustiva | Atazanavir (ATV) Reyataz | |||
| Emtricitabine (FTC) Emtriva | Etravirine (ETR) Intelence | Darunavir (DRV) Prezista | |||
| Lamivudine (3TC) Epivir | Nevirapine (NVP) Viramune | Fosamprenavir (FPV) Lexiva | |||
| Stavudine (d4T) Zerit | Rilpivirine Edurant | Indinavir (IDV) Crixivan | |||
| Tenofovir (TDF, TFV) Viread | lopinavir/ritonavir (LPV/r) Kaletra | ||||
| Zidovudine (AZT, ZDV) Retrovir | Nelfinavir (NFV) Viracept | ||||
| Ritonavir (RTV) Norvir | |||||
| Combination Drugs | Saquinavir (SQV) Invirase | ||||
| Atripla (efavirenz/emtricitabine/tenofovir) | Tipranavir (TPV) Aptivus | ||||
| Combivir (lamivudine/zidovudine) | |||||
| Complera (emtricitabine/rilpivirine/tenofovir) | |||||
| Epzicom (abacavir/lamivudine) | |||||
| Trizivir (abacavir/lamivudine/zidovudine) | |||||
| Truvada (emtricitabine/tenofovir) | |||||
NRTIs, Nucleoside reverse transcriptase inhibitors; NNRTI Non-nucleoside reverse transcriptase inhibitors.